Since its beginning in 2012, Cherish Women’s Cancer Foundation has funded several clinical trials and research programs through its research partner, Queensland Centre for Gynaecological Cancer (QCGC) Research.
These trials include:
- The LACE trial, which pioneered laparoscopic (keyhole) surgery for endometrial cancer
This was Cherish’s flagship research project for a number of years. Internationally this research trial has gained significant reputation, so that surgeons in almost all parts of the world know what the LACE trial is and where it is coming from.
- The study of a new tumour marker in endometrial cancer.
We have some weak preliminary evidence that we have found a tumour marker for endometrial cancer (EC). Until now there have been no proven markers available, which makes following up women with EC a dubious exercise. We are currently raising funds to be able to commission this research opportunity.
- Understanding and overcoming barriers to the use of Laparoscopic hysterectomy (called the LIGHT Study)
Almost 30,000 women in Australia will require a hysterectomy for a large number of reasons. From LACE it was found that laparoscopic hysterectomy is a better operation by all standards (shorter hospital stay, less pain, better recovery, less complications, less costs to funders). Nevertheless, only 12% of all hysterectomies are done laparoscopically and more than 40% are still done through an abdominal incision. This is the reason why QCGC Research started looking into barriers of the uptake of laparoscopic hysterectomy. Surgeons and patients have been interviewed and data collected to capture the options quantitatively. The result shall be a campaign to eradicate hysterectomy through an open incision!
Cherish has also just launched the CA125 smartphone app – a world first app that allows women diagnosed with ovarian or uterine cancer to self-monitor their tumour marker results.